Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label,randomised study to evaluate the efficacy and safety of dual-therapy [lopinavir and ritonavir plus lamivudine in Chinese ART-naïve HIV-infected patients

Next Previous
Trial Profile

An open label,randomised study to evaluate the efficacy and safety of dual-therapy [lopinavir and ritonavir plus lamivudine in Chinese ART-naïve HIV-infected patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Efavirenz; Tenofovir
  • Indications HIV infections
  • Focus Therapeutic Use

Most Recent Events

  • 01 Sep 2017 New trial record
  • 26 Jul 2017 Primary endpoint (Proportions of the patients with plasma HIV-RNA 50 copies/mL at week 48) has been met , as per results presented at the 9th International AIDS Society Conference on HIV Science.
  • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top